摘要
目的 分析程序性死亡受体-1(PD-1)/程序性死亡配体-1(PD-L1)抑制剂联合化疗治疗晚期宫颈癌的疗效及预后。方法 选取96例晚期宫颈癌患者为研究对象,根据随机数字表法将其分为对照组和观察组各48例。对照组采用常规化疗方案,观察组在对照组基础上联合PD-1/PD-L1抑制剂进行治疗。比较治疗6个周期后两组疗效,统计治疗6个周期内两组不良反应,观察治疗6个周期后两组患者生活质量(宫颈癌生活质量评价表)。结果 治疗6个周期后,观察组临床疗效及治疗有效率均高于对照组(P<0.05);治疗6个周期内,两组不良反应总发生率比较差异无统计学意义(P>0.05);观察组宫颈癌生活质量评价表躯体状况、生活状况、额外状况评分及总分均高于对照组(P<0.05)。结论 PD-1/PD-L1抑制剂联合化疗治疗晚期宫颈癌具有显著疗效,能改善患者生活质量。
Objective To analyze the effect and prognosis of programmed death 1(PD-1)/programmed death ligand 1(PD-L1)inhibitors combined with chemotherapy in the treatment of advanced cervical cancer.Methods A total of 96 patients with advanced cervical cancer were selected as the research subjects and divided into the control group and the observation group according to the random number table method,with 48 cases in each.The control group was treated with conventional chemotherapy regimen,and the observation group was treated with PD-1/PD-L1 inhibitors on the basis of the control group.Curative effect was compared between the 2 groups after 6 cycles of treatment,and adverse reactions that occurred in the 2 groups within 6 cycles of treatment were analyzed statistically.Quality of life(quality of life scale for patients with cervical cancer)of the two groups of patients after 6 cycles of treatment was observed.Results After 6 cycles of treatment,clinical efficacy and effective rate of treatment in the observation group were higher than those in the control group(P<0.05).Within 6 cycles of treatment,there was no statistically significant difference in the total incidence rate of adverse reactions between the 2 groups(P>0.05).The scores for physical condition,living condition and extra condition and total score of the quality of life scale for patients with cervical cancer in the observation group were higher than those in the control group(P<0.05).Conclusion PD-1/PD-L1 inhibitors combined with chemotherapy has significant effect in the treatment of advanced cervical cancer,and can improve the patients'life quality.
作者
徐月
田永巍
李宁
XU Yue;TIAN Yongwei;LI Ning(Kaifeng Central Hospital,Kaifeng,475000)
出处
《实用癌症杂志》
2024年第7期1167-1170,共4页
The Practical Journal of Cancer
基金
开封市科技发展计划项目(编号:2203070)。
